No abstract available
Publication types
-
Comparative Study
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiogenesis Inhibitors / economics
-
Angiogenesis Inhibitors / therapeutic use*
-
Bevacizumab / economics
-
Bevacizumab / therapeutic use*
-
Diabetic Retinopathy / drug therapy*
-
Diabetic Retinopathy / physiopathology
-
Fees and Charges
-
Humans
-
Insurance, Health, Reimbursement
-
Intravitreal Injections
-
Macular Edema / drug therapy*
-
Macular Edema / physiopathology
-
Medicare / economics
-
Randomized Controlled Trials as Topic / standards
-
Ranibizumab / economics
-
Ranibizumab / therapeutic use*
-
Receptors, Vascular Endothelial Growth Factor / economics
-
Receptors, Vascular Endothelial Growth Factor / therapeutic use*
-
Recombinant Fusion Proteins / economics
-
Recombinant Fusion Proteins / therapeutic use*
-
Treatment Outcome
-
United States
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
-
Visual Acuity / physiology
Substances
-
Angiogenesis Inhibitors
-
Recombinant Fusion Proteins
-
VEGFA protein, human
-
Vascular Endothelial Growth Factor A
-
aflibercept
-
Bevacizumab
-
Receptors, Vascular Endothelial Growth Factor
-
Ranibizumab